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Abstract
Background: Rofecoxib is a cyclo-oxygenase 2 selective inhibitor. This systematic review of
rofecoxib in acute pain examined studies in adults of analgesic efficacy over six hours, the amount
and quality of the evidence on extended duration of analgesia, and the quality and quantity of
evidence on adverse events.
Methods: Cochrane Library (issue 4, 2001), Biological Abstracts (March 2002), MEDLINE (March
2002) and PubMed (March 2002) were searched using rofecoxib as a free text term. The area under
the pain relief versus time curve was dichotomized using validated equations to derive the
proportion of patients on rofecoxib 50 mg or placebo with at least 50% pain relief over six hours.
This was used to calculate the number needed to treat for at least 50% pain relief over six hours
for rofecoxib compared with placebo. Information on duration of analgesia and adverse events was
also collected.
Results: Five included trials investigated 1,118 patients, of whom 211 received placebo and 464
received rofecoxib 50 mg. The NNT for rofecoxib 50 mg was 2.3 (95% confidence interval 2.0 to
2.6). The weighted mean remedication time was 1.9 hours for placebo (126 patients), 7.4 hours for
ibuprofen 400 mg (97 patients) and 13.6 hours for rofecoxib 50 mg (322 patients).
Conclusion: Rofecoxib at 2–4 times the standard daily dose for chronic pain is an effective single
dose oral analgesic in acute pain. Limitations in trial reporting constrain conclusions about longer
duration of analgesia and adverse event profile.
Background
Acute pain has been studied in single dose designs first
proposed by Beecher and colleagues [1,2] and formalized
by Houde and Wallenstein [3]. The problem with single
trials is that while they can demonstrate statistical superi-
ority of analgesic over placebo, variation because of ran-
dom chance means that, if small, they provide a poor
estimate of the size of the analgesic effect [4]. Combining
results from clinically homogeneous trials in a meta-anal-
ysis gives an accurate estimate of the extent of the analge-
sic effect when sufficient numbers of patients have been
randomized [4,5].
Clinical trials in acute pain normally last four to six hours,
because that is the duration of effect for most analgesics,
whether injected or as tablets, and for simple analgesics,
NSAIDs or opioids. Meta-analysis in acute pain has con-
centrated on the use of the area under the total pain relief
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versus time curve (TOTPAR), dichotomized into at least
50% pain relief or not [6]. It is not necessarily the only
measure available or the most relevant. The precedent ex-
ists at a primary research level for adopting remedication
as an outcome. Bullingham and colleagues [7] and Gibb
and colleagues [8] explored the measure of re-medication
in post-surgical patients subject to multiple dosing. A 'res-
cue factor' design was refined to demonstrate both analge-
sic efficacy and assay sensitivity). [9]. Farrar and
colleagues [10] extrapolated from re-medication data in
an effort to both define and demonstrate analgesic effica-
cy.
Despite these efforts, time to remedication has never be-
come a standard outcome in analgesic trials. One reason
for this might simply be the similarity in duration be-
tween commonly used analgesics. For rofecoxib, this
might be different. In arthritis 12.5 mg or 25 mg of ro-
fecoxib is given as a single dose once a day to control pain.
The acute pain dose of 50 mg is claimed to have pro-
longed analgesic activity [11].
The purpose of this systematic review and meta-analysis
of rofecoxib in acute pain was threefold. First to examine
all acute pain studies of analgesic efficacy in adults over
six hours for comparison with other analgesics in acute
pain. Second to examine the amount and quality of the
evidence presented on extended duration of analgesia.
Third to examine the quality and quantity of evidence on
adverse events.
Methods
QUORUM guidelines were followed [12]. Possible studies
for inclusion were sought through searching the Cochrane
Library (issue 4, 2001), Biological Abstracts (March
2002), MEDLINE (March 2002) and PubMed (March
2002) using rofecoxib as a free text term. The search strat-
egy used is detailed in Additional File 1. Abstracts were ex-
amined for possible inclusion if they were randomized
trials conducted in an acute pain setting, used rofecoxib
and a placebo or active comparator. Reference lists and re-
view articles were examined for possible additional refer-
ences, and in-house databases were also searched for
papers.
Criteria for inclusion for postoperative pain were: full
journal publication, randomized controlled trials which
included single dose treatment groups of oral rofecoxib
and placebo, double blind design, baseline postoperative
pain of moderate to severe intensity, patients over 15
years of age, at least 10 patients per group, and the pain
outcome measures of total pain relief (TOTPAR) or
summed pain intensity difference (SPID) over 4–6 hours
or sufficient data to allow their calculation. Pain measures
allowed for the calculation of TOTPAR or SPID were a
standard five point pain relief scale (none, slight, moder-
ate, good, complete), a standard four point pain intensity
scale (none, mild, moderate, severe) or a standard visual
analogue scale (VAS) for pain relief or pain intensity. Also
of interest was information on the time to remedication.
For adverse events, the primary outcome sought was the
proportion of patients experiencing any adverse event,
with secondary outcomes of patients experiencing partic-
ular adverse events. Although adverse events are often re-
ported inconsistently in acute pain trials [13], the
outcome of any patient experiencing any adverse event
was the least inconsistently reported.
Each report which could possibly be described as a rand-
omized controlled trial was read independently by at least
three authors and scored using a commonly-used three
item, 1–5 score, quality scale [14]. Consensus was then
achieved. The maximum score of an included study was 5
and the minimum score was 2. Authors were not blinded
because they already knew the literature.
For each trial, mean TOTPAR, SPID, VASTOTPAR or
VASSPID values for each treatment group were converted
to %maxTOTPAR by division into the calculated maxi-
mum value [15]. The proportion of patients in each treat-
ment group who achieved at least 50%maxTOTPAR was
calculated using valid equations [16–18]. The number of
patients randomized was taken as the basis for calcula-
tions, to produce an intention to treat analysis. The
number of patients with at least 50%maxTOTPAR was
then used to calculate relative benefit and NNT for ro-
fecoxib versus placebo. The same methods were used for
adverse events.
Relative benefit and relative risk estimates were calculated
with 95% confidence intervals using a fixed effects model
[19]. Heterogeneity tests were not used as they have previ-
ously been shown to be unhelpful [20,21], though homo-
geneity was examined visually [22]. Publication bias was
not assessed using funnel plots as these tests have been
shown to be unhelpful [23,24]. The number needed to
treat or harm (NNT and NNH) with confidence intervals
was calculated by the method of Cook and Sackett [25]
from the sum of all events and patients for treatment and
placebo. Cumulative calculation of NNT [5] was per-
formed by adding studies by year of publication, and al-
phabetically within a year.
Relative benefit or risk was considered to be statistically
significant when the 95% confidence interval did not in-
clude 1. NNT or NNH values were only calculated when
the relative risk or benefit was statistically significant, and
are reported with the 95% confidence interval. Calcula-
tions were performed using Microsoft Excel 2001 on a
Power Macintosh G4.BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/4
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Results
Searches identified twelve papers that were excluded. The
references and reasons for exclusion are given in Addition-
al File 2. Five studies were included [11,26–29]. Details of
the design, numbers of patients, outcomes, analgesic re-
sults, adverse events and quality scores are given in Addi-
tional File 3. Four of the five included trials were in a
dental pain setting after third molar extraction, and one
[29] was after orthopaedic surgery. The five trials studied
1,118 patients, of whom 211 received placebo and 464 re-
ceived rofecoxib 50 mg. Comparator analgesics included
ibuprofen 400 mg (117 patients in three trials), celecoxib
200 mg (91 patients in one trial), paracetamol 600 mg
plus codeine 60 mg (180 patients in one trial) and
naproxen sodium 550 mg (55 patients in one trial). Qual-
ity scores were 4 for four trials and 5 for one. All the in-
cluded studies were funded by Merck, the manufacturer of
rofecoxib.
At least 50% pain relief
All five trials gave or allowed the calculation of six-hour
TOTPAR and the derivation of the number of patients
with at least 50%maxTOTPAR. There was good agreement
between the five studies (Figure 1). Overall 252/464 pa-
tients (54%) given rofecoxib 50 mg had at least 50% max-
TOTPAR over six hours, compared with 24/211 patients
(11%) with placebo. The NNT for one patient to have at
least half pain relief over six hours was 2.3 (2.0 to 2.6)
(Table 1). Cumulative meta-analysis of the five trials (Fig-
ure 2) shows that the 95% confidence interval of the cal-
culated NNT fell within ± 0.5 NNT of the overall mean
(1.8 to 2.8) when 500 patients had been randomized.
Figure 1
L'Abbe plot of percent of patients with 50% pain relief in pla-
cebo controlled trials of rofecoxib 50 mg
Figure 2
Cumulative meta-analysis of placebo controlled clinical trials
of rofecoxib 50 mg
Table 1: Number, number-needed-to-treat/harm and relative benefit/risk estimate for placebo controlled clinical trials of rofecoxib 50 
mg
Number/total (%) with the outcome with
Outcome Number of trials Rofecoxib 50 mg Placebo Relative benefit/risk 
(95% CI)
NNT/H (95% CI)
At least 50% pain 
relief
5 (56) (11) 4.8 (3.3 to 7.2) 2.3 (2.0 to 2.6)
Any adverse event 2 (28) (33) 0.69 (0.44 to 1.08) Not calculated
Nausea 3 (7) (17) 0.48 (0.26 to 0.88) -11 (-6 to -40)
Vomiting 3 (4) (12) 0.36 (0.16 to 0.79) -12 (-7 to -46)BMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/4
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Remedication time
Onset of analgesia with rofecoxib 50 mg appeared to be
generally the same as with comparator analgesics. Trials
tried to discourage remedication within 90 minutes, and
two patients in one trial were excluded because they re-
medicated within 90 minutes, one on placebo and one on
rofecoxib 50 mg [26]. This was not reported consistently
(Additional File 3). The percentage of patients remedicat-
ing within two hours was given in one study [26], and
within 24 hours in two [11,27]. Only one study (.([27]
gave cumulative remedication rates over the duration of
the study. Median time to remedication was given in three
studies [11,27,28], and this allowed the calculation of a
mean of the three trials weighted by the number of pa-
tients. For placebo the weighted mean time to remedica-
tion from 126 patients in three trials was 1.9 hours. For
rofecoxib 50 mg the weighted mean time to remedication
from 322 patients in three trials was 13.6 hours. For ibu-
profen 400 mg the weighted mean time to remedication
from 97 patients in two trials was 7.4 hours.
Adverse events
Adverse events were not reported consistently (Additional
File 3). Two trials reported the proportion of patients hav-
ing any adverse event. An adverse event was reported by
33% of patients on placebo and 28% of those on rofecox-
ib 50 mg (not significantly different, Table 1). Nausea and
vomiting were reported separately in three dental trials,
and both occurred significantly less frequently with ro-
fecoxib 50 mg than with placebo (Table 1). For both there
were negative numbers needed to harm (-11 and -12 re-
spectively), showing that for every 11 or 12 patients given
rofecoxib, one fewer was nauseous or vomited than with
placebo. There were few events, though, with only 44 nau-
seated patients and only 27 who vomited in the three tri-
als of rofecoxib 50 mg comparable with 34 nauseated
patients and only 22 who vomited in the two trials of ibu-
profen 400 mg.
Discussion
The five included studies were of generally high reporting
quality (quality scores of 4 or 5), known to be associated
with minimal reporting bias [30,31]. They all had a place-
bo control, used standardized pain intensity and relief
scores in adult patients with established pain of moderate
or severe intensity, and measured outcomes over at least
six hours. The pain models, third molar dental extraction
and orthopaedic surgery, are commonly used in research
and choice of model does not appear to influence results
in single-dose analgesic studies when patients are able to
take oral medication [13]. Comparison of rofecoxib 50
mg with other analgesics over six hours is legitimate, be-
cause the same outcome was measured in the same way in
the same patients over the same period of time, and with
same comparator.
Compared with placebo, the NNT for at least 50% pain re-
lief over six hours was 2.3 (2.0 to 2.6). Table 2 collects
NNTs for a number of common oral analgesics and intra-
muscular morphine from recent meta-analyses [32,13]
and unpublished updates of other published Cochrane re-
views [33,34]. Rofecoxib 50 mg is comparable with other
doses of oral NSAIDs and intramuscular morphine.
For rofecoxib 50 mg this may not fully reflect its efficacy
compared with these other analgesics, because rofecoxib
50 mg may have a longer duration of action. In the five in-
cluded trials duration was inconsistently reported, howev-
er, with median remedication times in three trials (but
without dispersion) and percentage remedicated at two
hours in one trial and 24 hours in two trials. This disparity
in reporting allowed only the crudest analysis of weighted
mean remedication time. This was 1.9 hours for placebo,
7.4 hours for ibuprofen 400 mg and 13.6 hours for ro-
fecoxib 50 mg. The figures of 7.4 hours for ibuprofen 400
mg and 1.9 hours for placebo is in agreement with a larger
unpublished analysis (Barden et al, unpublished observa-
tions). The extended time to remedication for rofecoxib
Table 2: Rofecoxib 50 mg numbers-needed-to-treat compared with common analgesics
Drug and dose Number of patients in the comparison NNT (95%CI)
Rofecoxib 50 mg 675 2.3 (2.0 to 2.6)
Diclofenac 50 mg 738 2.3 (2.0 to 2.7)
Ibuprofen 400 mg 4703 2.4 (2.3 to 2.6)
Morphine 10 mg (IM) 946 2.9 (2.6 to 3.6)
Paracetamol 1000 mg 2759 3.8 (3.4 to 4.4)
Paracetamol 600/650 mg + codeine 60 mg 1123 4.2 (3.4 to 5.3)
Aspirin 600/650 mg 5061 4.4 (4.0 to 4.9)
Compiled from published and unpublished systematic reviewsBMC Anesthesiology 2002, 2 http://www.biomedcentral.com/1471-2253/2/4
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50 mg may represent a real clinical advantage where the
problem is not a lack of effective analgesics, but rather ef-
fective analgesics ineffectively delivered [35], and given
that using a relatively large dose has no disadvantages.
The efficacy of rofecoxib in these five classical clinical an-
algesic assays is in contrast to two randomized compari-
sons of rofecoxib with placebo when given before the
operation in adults [36] and children [37]. The methodo-
logical difficulties and lack of effect of preemptive analge-
sia have been pointed out previously [38,39]. In these two
trials additional difficulties were the large between-indi-
vidual variation in morphine consumption in adults [36],
and the use of a novel (unlicensed) syrup formulation of
rofecoxib in children [37]. Lack of a demonstrable analge-
sic effect in preemptive studies does not negate a substan-
tial postoperative effect when patients both have pain and
can swallow.
There was no consistent pattern of adverse event reporting
in the five included trials. Two trials had information on
any patient with any adverse event (Table 1), with no dif-
ference between rofecoxib 50 mg and placebo. In three tri-
als information on patients suffering nausea and vomiting
was available, showing that these adverse events occurred
less frequently with rofecoxib 50 mg than placebo. The
amount of information (number of patients randomized)
was insufficient to make any authoritative statement
about adverse events, or compare the adverse event profile
of rofecoxib 50 mg in single doses with other single dose
analgesics. Adverse events in single-dose studies are often
poorly reported, and of limited value [40].
In clinical practice, NSAIDs are associated with acute renal
failure in patients with impaired renal function [41,42]
and with congestive heart failure in older people with a
prior history of heart disease [43]. Acute renal failure after
surgery occurs in 1 patient in 1000 after major surgery
[44], though it is not clear how much of this is specifically
due to the NSAID. For coxibs, especially at high doses,
similar caution should be used in patients with pre-exist-
ing renal or cardiac conditions as apply to the use of
NSAIDs. The slope of the adverse event dose-response
may be steeper than for analgesia.
These published reports were insufficiently detailed for
calculation of numbers needed to treat for durations long-
er than six hours. Some information was available for
TOTPAR calculated to eight hours, but not in a dichoto-
mous format. TOTPAR is not normally distributed, and
mean values are not meaningful [45]. For times longer
than six hours, and for duration of analgesia and adverse
event profiles, more detailed information from individual
patients would be required.
Conclusions
Rofecoxib at a dose 2–4 times the standard daily dose for
chronic pain is an effective single dose oral analgesic in
acute pain. Limitations in trial reporting constrain conclu-
sions about longer duration of analgesia and adverse
event profile.
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